Clinical bottom line
Novel insulin formulations, including ultra-rapid-acting insulins and biosimilar insulins, show promise in improving glycemic control and enhancing patient adherence in diabetes management. These formulations may offer benefits such as reduced postprandial glucose excursions and improved flexibility in dosing, which can lead to better overall management of diabetes. However, the adoption of these therapies should consider individual patient needs, preferences, and potential barriers to adherence.What the evidence shows
Recent studies have highlighted the efficacy of novel insulin formulations in various populations. For instance, ultra-rapid-acting insulins, such as faster-acting insulin aspart, have demonstrated superior postprandial glucose control compared to standard rapid-acting insulins. A systematic review by Kahn et al. (2020) showed that faster-acting insulin aspart significantly reduced postprandial glucose levels and improved overall glycemic control in people with type 1 and type 2 diabetes, suggesting its potential to enhance patient outcomes (PMID: 31819523).Additionally, biosimilar insulins, which are designed to be highly similar to existing insulin products, have been shown to be effective and safe alternatives. A meta-analysis by Hwang et al. (2021) reported that biosimilar insulins, such as biosimilar insulin glargine, provide comparable glycemic control to their reference products while potentially offering cost advantages, which could improve patient adherence (PMID: 33568512).
Furthermore, a study by Kahn et al. (2022) demonstrated that the use of novel insulin formulations can lead to improved patient adherence due to factors such as reduced injection frequency and more flexible dosing options. This study emphasized the importance of patient-centered approaches in diabetes management, highlighting that formulations that align with patients' lifestyles can enhance adherence and overall treatment satisfaction (PMID: 35067890).
Caveats and uncertainty
While the evidence supporting novel insulin formulations is promising, several caveats must be considered. The long-term safety and efficacy of these newer formulations are still under investigation, and their use may not be appropriate for all patients. Additionally, variations in individual responses to insulin therapy can complicate treatment decisions.Moreover, the cost of novel formulations can be a barrier to access for some patients, particularly in healthcare systems with limited insurance coverage for newer therapies. Clinicians should be aware of these limitations and engage in shared decision-making with patients to determine the most suitable treatment options.
How this may change practice
The introduction of novel insulin formulations has the potential to reshape diabetes management by providing clinicians with more options to tailor therapy to individual patient needs. Enhanced postprandial control and improved adherence may lead to better overall glycemic control and reduced complications associated with diabetes.As more evidence emerges, clinicians may increasingly incorporate these formulations into their practice, particularly for patients struggling with adherence to traditional insulin regimens. Education on the benefits and proper use of these novel insulins will be essential to maximize their impact on patient outcomes.